HEALTH OF WOMAN. 2017.9(125):51–58; doi 10.15574/HW.2017.125.51

Voloshena N. M., Zvantseva E. D.
Zaporizhzhya Medical Academy of Postgraduate Education
Zaporizhzhya Regional Clinical Cancer Dispensary

The problem of early diagnostics and prevention of cervical cancer is actual in Ukraine.The leading etiologic factor in the genesis of cervical neoplasia and a number of other organs is Human papillomavirus (HPV). The human papillomavirus is sexually transmitted and has high contagiosity. Cancer prevention consists in effective screening, early detection and treatment of pathological changes in the cervix. The aggressive treatment of diseases caused by (HPV) has been replaced by a tactic of a differentiated approach, taking into account to the age of the woman and her reproductive plans.
The objective: was to study the efficacy and tolerability of the combined use of Proteflazid® systemically in drops form and locally in the form of suppositories for 3 months in patients with cervical intraepithelial neoplasia (CIN) of lung and moderate severity (CIN 1 and CIN 2) associated with the human papillomavirus (HPV); determination on the basis of the results of the need for further destructive treatment.
Materials and methods. For the period from July 2016 to September 2017, we examined and treated 86 women with morphologically confirmed intraepithelial neoplasia of the cervix associated with HPV infection.
Results. Based on the performed studies, it was found that 6 months after treatment with Proteplasid® systemically and locally for 3 months, regression of CIN was noted in 93% of patients. In all cases, a reduction in viral load of more than 2 Lg of HPV/105, which is a marker of the effectiveness of antiviral therapy, has been recorded. Six months after treatment in 84% of patients and 9 months in 88%, there was complete elimination of HPV or reduced viral load to clinically insignificant values – less than 3 Lg.
Conclusion. The drug Proteflazid® suppositories and drops contributes to the elimination of human papillomavirus (HPV) and other viral-bacterial infections and reduces the risk of cervical neoplasia.
Key words: cervical cancer, screening, cervical neoplasia, Human papillomavirus, viral-bacterial infections, Proteflazid®.

References
1. Amjadi F, Salehi E, Medhdizadeh M et al. 2014. Role of the innate immunity in female reproductive tract. Adv. Biomed. Res. 3:1–15. https://doi.org/10.4103/2277-9175.124626; PMid:24592358 PMCid:PMC3928842

2. Atkinson W, Wolfe S, Hamborsky J. Human Papillomavirus. Epidemiology and Prevention of Vaccine Preventable Diseases. The Pink Book: Course Textbook. 12th Edition Second Printing. 2012.

3. Arbyn М, Anttila А, Jordan et al. 2008. European guidelines for quality assurance in cervical cancer screening Second Edition.

4. Berzolla CE. 2007, Nov. Dysplasia and malignancy in endocervical polyps. J Womens Health (Larchmt) 16(9):1317–1321.

5. Bruni L, Diaz M, Castellsague X. 2010, December 15. Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings. J. Infect. Dis. 202:1790.

6. Cole AM. 2006. Innate host defense of human vaginal and cervical mucosae. Curr Top Microbiol Immunol. 306:199–230.

7. Comprehensive Cervical Cancer Control: A guide to essential practice, 2010, World Health Organization. www://whqlibdoc.who.int/publications/2006/9241547006_eng.pdfua=1.

8. Hein M, Valore EV, Helmig RB et al. 2002. Antimicrobial factors in cervical mucus plug. Am J Obstet Gynecol. 187:137–44. https://doi.org/10.1067/mob.2002.123034; PMid:12114901

9. Herbert A, Bergeron C, Wiener H et al. 2007. European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology. Cytopathology 18:213–219. https://doi.org/10.1111/j.1365-2303.2007.00469.x; PMid:17635161

10. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid–based cytology. 2007.

11. Fahey JV, Sentman CL, Pioli PA et al. 2005. Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev. 206:306–335. https://doi.org/10.1111/j.0105-2896.2005.00287.x; PMid:16048557

12. Jackson S, Mestecky J, Moldoveanu Z et al. Appendix I: collection and processing of human mucosal secretions. Mucosal Immunology, 3rd edn. Amsterdam. The Netherlands, Elsevier Academic Press. 2005: 1647–1659.

13. Kaminsky VV, Litus AI, Grynevych OI et al. 2015. Proteflazid: Efficacy and safety in urogenital herpes virus infection (systematic review). Science and Education Studies 2(16):705–727.

14. Kornatcska A, Revenko O, Grynevych O et al. 2016. Therapeutic efficacy and tolerability profiles of Proteflazid®, suppository and drops among the patients with herpesvirus infection in the exacerbation phase. European Journal of Scientific Research 1(9):506–522.

15. Lee-Huang S, Maiorov V, Huang PL et al. 2005. Structural and functional modeling of human lysozyme reveals a unique nona peptide, HL9, with anti–HIV activity. Biochemistry 44:4648–4655. https://doi.org/10.1021/bi0477081; PMid:15779891

16. Russell MW, Mestecky J. 2002. Humoral immune responses to microbial infections in the genital tract. Microbes and infection 4:667–677. https://doi.org/10.1016/S1286-4579(02)01585-X

17. Zaporozhan VN, Marichereda VG, Dimcheva LI. 2014. Застосування флавонових глікозидів у терапії генітальної папіломавірусної інфекції у жінок. Application of flavonivyh glycosides papilomavirusnoy therapy of genital infection in women. Journal of Health Sciences 4(12):93–104. ISSN 1429–9623 / 2300–665X.

18. Ventskovsky В, Grynevych O, MD, Mikhailov V, Lesnikova M, Yaschenko L, Broun T. 2016, January–June. Proteflazid® in the treatment and prevention of human herpesvirus infection in pregnant women: a meta–analysis of clinical trials results. American Journal of Science and Technologies 1(21):983–1002.

19. Bayev AI. Kuziyeva GD. Silayev DV i dr. 2011. Obosnovaniye primeneniya Proteflazida® v kompleksnoy terapii mikst–IPPP (Soobshcheniye 3). Voprosy dermatologii i venerologii 3–4(47–48):31–33.

20. Benyuk VA. Grinevich AI. Usevich IA i dr. 2016. Terapevticheskaya effektivnost suppozitoriyev Proteflazid® pri smeshannoy urogenitalnoy virusno-bakterialnoy infektsii. Zdorovye zhenshchiny 2(106):162–166.

21. Voloshina NN. Voloshin NA. 2010. Skrining i profilaktika raka sheyki matki. Zaporozhye. Pechatnyy mir:155.

22. Vovk IB. Revenko OA. Danilyuk OI. 2002. Ispolzovaniye flavonoidov v kompleksnom lechenii zhenshchin s vospalitelnymi zabolevaniyami genitaliy virusno-bakterialnoy etiologii. Zdorovye zhenshchiny 4(12):43–45.

23. Voytenko GN. Kokhanov IV. 2016. Farmakoekonomicheskoye obosnovaniye primeneniya preparata proteflazid v terapii papillomavirusnoy infektsii. «Retsept». 19;3.

24. Hodlevska NA, Starovir AV. 2012. Efektyvnist systemnoho ta mistsevoho zastosuvannia preparatu Proteflazid u likuvanni patolohii shyiky matky, sprychynenoi papilomavirusnoiu infektsiieiu. Zdorove zhenshchynы 3(69):80–83.

25. Hodlevska NA, Starovir AV. 2017. Klinichna efektyvnist mistsevoho zastosuvannia vahinalnykh supozytoriiv Proteflazid® u likuvanni tservikalnoi intraepitelialnoi neoplazii lehkoho ta pomirnoho stupeniv, zumovlenoi virusom papilomy liudyny. Zdorove zhenshchynы 2(118):55–60.

26. Kaminskiy VV. Shalko MN. Vorobyeva LI i dr. 2015. Proteflazid: spetsificheskaya aktivnost v doklinicheskikh issledovaniyakh. effektivnost i bezopasnost primeneniya v klinicheskoy praktike pri zabolevaniyakh. vyzvannykh virusom papillomy cheloveka. Zdorovye zhenshchiny 3(99):128–138.

27. Ligirda NF. Svintsitskiy VS. 2016. K voprosu organizatsii skrininga raka sheyki matki v Ukraine. Meditsinskiye aspekty zdorovia zhenshchin 6(103):69–73.

28. Lyhyrda NF. 2017. Praktychna kolposkopiia. K:198.

29. Marsheta Zh, Dekamp F. 2009. Kolposkopyia. Metod y diahnostyka. Per. s frants.; pod obshchei red. Prylepskoi VN. M, MEDpress-ynform:200.

30. Patologiya sheyki i tela matki: rukovodstvo dlya vrachey akusherov–ginekologov. onkologov. tsitologov. gistologov. prepodavateley i studentov med. in-tov. Pod red. EV Kokhanevich. Nezhin: Gidromaks. 2009:350.

31. Rak v Ukraini, 2014–2015. Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby. Biuleten natsionalnoho kantser–reiestru Ukrainy. 2016. 17:48–50.

32. Rogovskaya SI. 2005. Papillomavirusnaya infektsiya u zhenshchin i patologiya sheyki matki. M. GEOTAR-Media:141.

33. Rogovskaya SI. 2013. Prakticheskaya kolposkopiya. 3 izd.. ispr. i dopoln. M. GEOTAR-Media:240.

34. Romashchenko OV, Rudenko AV. 2002. Proteflazid v kompleksnii terapii zapalnykh zakhvoriuvan henitalii u zhinok. Pediatriia, akusherstvo ta hinekolohiia 3:89–94.

35. Rykova O. Bogomaz T. 2017. Terminologicheskaya sistema TBS 2014 goda. Chto novogo? Z turbotoyu pro zhіnku 1(76):5–6.

36. Taran OA. Bulavenko OV. 2014. Sovremennyye aspekty kombinirovannoy terapii tservikalnykh neoplaziy. assotsiirovannykh s papillomavirusnoy infektsiyey. Zdorovye zhenshchiny 2(88):38–42.

37. Titmushsh E. Adams K. 2009. Sheyka matki. Tsitologicheskiy atlas. Perevod s angl.; pod red. NI Kondrikova. M. Prakticheskaya meditsina:255.

38. Kaminsky VV, Chernyshov VP, Grynevych OI et al. 2017. Proteflazid® and local immunity in diseases caused by human papillomavirus and mixed urogenital infections. Pol Med J. XLII(249):110-115.